Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Genpharmasec Ltd (531592)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 531592 NSE: Trading | Small Cap | Genpharmasec Share Price
₹1.14 0.00 (0.00%)
As on 21-Sep'26 16:59
Genpharmasec Ltd (531592)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 531592 NSE: Trading | Small Cap | Genpharmasec Share Price
₹1.14 0.00 (0.00%)
As on 21-Sep'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹63 Cr.
Current Price
₹1.1
52-Week Low / High
₹1 / 2
TTM EPS
₹0
TTM Sales
₹178 Cr.
Book Value per Share
₹1.2
P/E Ratio
0.00
Lower than its 5-year historical median
Industry PE
39.7
Price to Book (P/B)
0.96
Lower than its 5-year historical median
Price to Sales (P/S)
0.36
Lower than its 5-year historical median
EV/EBITDA
21.11
Lower than its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
1.90%
Underperforms industry median
Return on Capital Employed (ROCE)
3.43%
Underperforms industry median
Return on Assets (ROA)
1.64%
Operating Profit Margin
0.2%
Net Profit Margin
3.65%
Gross Profit Margin
8%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
8.39%
Operating Profit Growth (1 Year)
-
60%
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
29.98%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹10 Cr.
Equity
₹55.4 Cr.
Face Value
₹1
All Time Low / High
₹0.13 / 10.81
Check Before You Invest
M-Cap below 100cr DeciZen not available
Is Genpharmasec Ltd a good quality company?
Genpharmasec Ltd is a quality company, based on a multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Genpharmasec Ltd performance compare with that of its Peers?
Revenue growth of Genpharmasec Ltd vs industry peers?
Genpharmasec Ltd revenue CAGR is 0.00%, compared to the industry median CAGR of 0%, indicating stable growth and maintaining its market share.
Promoter shareholding and pledge status of Genpharmasec Ltd?
Promoters hold 29.98% of the Genpharmasec Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Genpharmasec Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 21% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Genpharmasec Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good
Value Creation ⓘ
| Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 189% | 13.6% | 48.6% | 2.7% | 5.9% | 7.6% | -2.5% | 2% | 2% | 5.4% | - |
| Value Creation Index ⓘ | 12.5 | 0.0 | 2.5 | -0.8 | -0.6 | -0.5 | -1.2 | -0.9 | -0.9 | -0.6 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 0 | 0.5 | 0.1 | 0.4 | 16.5 | 21.3 | 27.3 | 25.5 | 30.4 | 33 | 164 |
| Sales YoY Gr. | - | NA | -83.3% | 375% | 4,242.1% | 29.2% | 28.2% | -6.6% | 19.2% | 8.4% | - |
| Adj EPS ⓘ | 0 | 0 | 0.1 | 0 | 0 | 0 | -0 | 0 | -0 | 0 | 0.1 |
| YoY Gr. | - | NA | 200% | -88.9% | 200% | 0% | -100% | NA | -100% | NA | - |
| BVPS (₹) ⓘ | -0.1 | -1.7 | -1.6 | 0.6 | 0.5 | 0.4 | 0.3 | 0.3 | 1.2 | 1.2 | 1.3 |
| Adj Net Profit ⓘ | 0 | 0 | 0.1 | 0.2 | 1 | 1.3 | -0.2 | 1.1 | -0.1 | 2.4 | 6 |
| Cash Flow from Ops. ⓘ | 0.1 | -0.1 | 0.1 | -6.4 | 1.4 | -2.1 | -2.3 | -3.1 | -2.3 | 3.5 | - |
| Debt/CF from Ops. ⓘ | 9.7 | -21.3 | 6.8 | 0 | 0 | 0 | 0 | -1 | -1.4 | 0.9 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | 14.8% | 6.5% | 8.4% | ||||
| Adj EPS ⓘ | NA | 5.9% | NA | NA | ||||
| BVPSⓘ | NA | 19.6% | 53.8% | 2.6% | ||||
| Share Price | 21% | -24.8% | -21.5% | -43.6% | ||||
Key Financial Parameters ⓘ
| Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | -1.8 | -1.7 | -5.4 | 2.1 | 5 | 6.3 | -1.2 | 7.1 | -0.2 | 3.7 | 7.9 |
| Op. Profit Mgn % ⓘ | 0 | -12.4 | -31.4 | -23.2 | 4 | 5.6 | -1.9 | 1 | 0.5 | 1.3 | 1.7 |
| Net Profit Mgn % ⓘ | 0 | 3.2 | 58.5 | 57.4 | 6.1 | 5.9 | -0.8 | 4.3 | -0.3 | 7.3 | 3.4 |
| Debt to Equity ⓘ | -1.1 | -1.2 | -1.1 | 0 | 0 | 0 | 0 | 0.2 | 0.1 | 0.1 | - |
| Working Cap Days ⓘ | 0 | 199 | 1,152 | 4,331 | 279 | 281 | 227 | 239 | 287 | 473 | 66 |
| Cash Conv. Cycle ⓘ | 0 | 11 | -1,804 | 17 | 42 | 123 | 128 | 170 | 175 | 157 | 22 |
Valuation of Genpharmasec - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'23 | Mar'24 | Mar'25 |
|---|---|---|---|
| Sales | 25.52 | 30.41 | 33.72 |
| Operating Expenses ⓘ + | 25.26 | 30.36 | 33.64 |
| Operating Profit ⓘ | 0.26 | 0.05 | 0.08 |
| Operating Profit Margin (%) | 1.0% | 0.2% | 0.2% |
| Other Income ⓘ + | 0.10 | 0.66 | 3.06 |
| Interest ⓘ | 0.06 | 0.41 | 0.45 |
| Depreciation ⓘ | 0.02 | 0.04 | 0.81 |
| Profit Before Tax ⓘ | 0.28 | 0.25 | 1.88 |
| Tax ⓘ | -0.84 | 0.42 | 0.65 |
| Profit After Tax | 1.12 | -0.17 | 1.23 |
| PAT Margin (%) | 4.4% | -0.6% | 3.7% |
| Adjusted EPS (₹) | 0.0 | 0.0 | 0.0 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% |
| PARTICULARS | Mar'23 | Mar'24 | Mar'25 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 15.33 | 64.40 | 65.16 | ||||||||
| Debt + | 3.08 | 3.21 | 3.15 | ||||||||
| Minority Interest | 0 | 0.14 | 0.12 | ||||||||
| Trade Payables | 1.37 | 2.38 | 8.26 | ||||||||
| Others Liabilities ⓘ | -0.75 | 0.58 | 2.74 | ||||||||
| Total Liabilities ⓘ | 19.03 | 70.70 | 79.43 | ||||||||
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 0.10 | 0.84 | 7.58 | ||||||||
| CWIP ⓘ | 0 | 0 | 0 | ||||||||
| Investments ⓘ | 0.95 | 19.32 | 18.84 | ||||||||
| Inventories | 9.68 | 8.84 | 8.20 | ||||||||
| Trade Receivables | 5.71 | 9.10 | 13.60 | ||||||||
| Cash Equivalents | 1.99 | 18.83 | 5.27 | ||||||||
| Others Assets ⓘ | 0.60 | 13.76 | 25.94 | ||||||||
| Total Assets ⓘ | 19.03 | 70.70 | 79.43 | ||||||||
| PARTICULARS | Mar'23 | Mar'24 | Mar'25 |
|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | -3.06 | -2.95 | 2.99 |
| Cash Flow From Investing Activity ⓘ + | 0.36 | -28.06 | -15.30 |
| Cash Flow From Financing Activity ⓘ + | 3.08 | 47.85 | -1.25 |
| Net Cash Flow ⓘ | 0.39 | 16.84 | -13.56 |
| PARTICULARS | Mar'23 | Mar'24 | Mar'25 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 7.34 | -0.42 | 1.9 | |||||||
| ROCE (%) | 1.83 | 1.53 | 3.43 | |||||||
| Asset Turnover Ratio | 1.34 | 0.68 | 0.45 | |||||||
| PAT to CFO Conversion(x) | -2.73 | N/A | 2.43 | |||||||
| Working Capital Days | ||||||||||
| Receivable Days | 81.70 | 88.90 | 122.80 | |||||||
| Inventory Days | 138.40 | 111.20 | 92.20 | |||||||
| Payable Days | 21.40 | 28.20 | 65.70 | |||||||
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Genpharmasec Ltd FAQs
The current trading price of Genpharmasec on 21-Sep-2026 16:59 is ₹1.14.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 20-Sep-2026 the market cap of Genpharmasec stood at ₹63.12 Cr
The latest P/E ratio of Genpharmasec as of 20-Sep-2026 is 11.57.
The latest P/B ratio of Genpharmasec as of 20-Sep-2026 is 0.86.
The 52-week high of Genpharmasec is ₹2.11 and the 52-week low is ₹0.75.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Genpharmasec is ₹164 ( Cr.) .
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Genpharmasec Ltd is a below average quality company.
The key valuation ratios of Genpharmasec Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Genpharmasec Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
About Genpharmasec Ltd
Adi Rasayan Limited was incorporated as Public Limited Company on November 16, 1992 and obtained Commencement of Business Certificate on November 20, 1992 with the object, of manufacturing and trading in organic and inorganic chemicals dyes and pigments. The company was promoted by Sanjay J. Adani, Dinesh H. Desai, Dahyabhai Patel, Vikram R. Shah and Mitesh J. Adani and family members.
Subsequently, during October 1994 Shashikant M. Gandhi joined as co-promoter. In early 1993, it was decided by the, Board to set up the project. In April 1993 land admeasuring 19095.36 square metres was acquired at GIDC Industrial Estate, Panoli, Ankleshwar, Bharuch District, Gujarat, for the project. In July 1994, and in December 1994 the company obtained acknowledgements of Memoranda for its products. The company is presently implementing the project. The company is also carrying out a small amount of trading in chemicals.
Adi Rasayan`s registered office is located at Gujarat, India.
Products & Services
- Pigments, natural
- Pigments, synthetic
You have 49 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
